logo-loader
ASX:PXS PINK:PXSLY

Pharmaxis Ltd

Market:
ASX
Market Cap:
$35.72 m
Price
0.09 AUD
Change
2.27%
52 weeks high
0.29
52 weeks low
0.05

Pharmaxis Ltd is an Australian pharmaceutical research company with expertise in developing drugs for inflammatory and fibrotic diseases and focussed on myelofibrosis. The company has a highly productive drug discovery engine, drug candidates in clinical trials and two approved respiratory products in global markets generating ongoing revenue.

Bronchitol®

Bronchitol is approved for the treatment of cystic fibrosis to help patients clear mucus from their lungs. It is a precision spray-dried form of mannitol, delivered to the lungs by a specially designed, portable inhaler. Bronchitol works by rehydrating the airway/lung surface and promoting a productive cough.

Bronchitol® was the subject of three large scale clinical trials and is approved and marketed in Europe, Russia, Australia and the United States. The third clinical trial was the final trial required to secure approval in the United States and was primarily funded by Pharmaxis’s US partner Chiesi Farmaceutici SpA . Bronchitol received FDA approval in October 2020. Commercial launch of Bronchitol in the US is scheduled for Q2 2021.

Bronchitol is approved for marketing for the treatment of cystic fibrosis patients aged over six years in Australia and Russia and for patients aged 18 years and over throughout the European Union and the United States. In all markets, patients are required to have a tolerance test prior to being prescribed Bronchitol to ensure that they are not hyper responsive to mannitol.

Clinical trials have shown that Bronchitol helps to increase mucus clearance, and improve the lung function and the quality of life of people living with cystic fibrosis.

(click here for more information)


Aridol®

Pharmaxis' first commercial product, Aridol is an innovative lung function test designed to help doctors diagnose and manage asthma by detecting active airway inflammation through measuring airway hyper-responsiveness. Patients inhale increasing doses of Aridol via a simple hand-held device. Respiratory clinicians administering the test measure the patient's lung function to identify airway inflammation which can assist doctors in providing appropriate asthma treatment. Aridol is approved for sale in Australia, major European countries and South Korea. It is the first and only approved Europe-wide approved bronchial challenge test and the world's first approved indirect challenge test for asthma, a condition which affects 52 million people worldwide. Aridol is used in investigator-sponsored clinical trials worldwide. It has also been included in both international and Australian official guidelines for managing asthma.


PRODUCT PIPELINE

Drug Discovery

Pharmaxis aims to improve success rates, minimise drug discovery costs and speed up development timelines by focusing on targets that have been independently validated in diseases with limited treatment options and where its amine oxidase platform can be utilised.

(click here for information on this project)


Amine Oxidase Platform

There is significant interest among leading clinicians and pharmaceutical companies in inflammatory and fibrotic diseases. Pharmaxis’ amine oxidase platform enables the synthesis of inhibitors with different pharmacological and pharmacokinetic profiles to potentially treat a number of inflammatory and fibrotic diseases.

The inhibition of amine oxidase based enzymes has broad potential applications.

While Pharmaxis’ primary focus is the development of PXS-5505 for myelofibrosis, the drug also has potential in several other cancers including liver and pancreatic cancers where it aims to breakdown the fibrotic tissue in the tumour and enhance the effect of existing chemotherapy.

Other drugs in development include:

  • PXS-5382 (LOXL2 inhibitor) – anti fibrotic drug for CKD, IPF, NASH
  • PXS-6303 (topical pan LOX inhibitor) - anti fibrotic drug for skin scarring including burns, established scars, and keloids
  • PXS-4699 (dual SSAO/MAOB inhibitor) – anti inflammatory drug for muscular dystrophies such as DMD
  • PXS-5370 (dual SSAO/MPO inhibitor) - anti inflammatory drug for multiple indications.
  • PXS-4728 (SSAO inhibitor) - anti inflammatory drug currently being assessed for potential clinical applications..


Other Pipeline Assets

Orbital® Dry Powder Inhaler

Pharmaxis is also developing an innovative inhaler device to deliver high payloads of drugs to the lungs: - The Orbital Dry Powder Inhaler

 

Last updated 10th November 2020

Malcolm J McComas
BEc LLB - Independent Chairman

Malcolm has been a member of the Board of Directors since July 2003 and Chairman of the Board since 2012. He is a company director and a former investment banker and commercial lawyer. Malcolm is the principal of McComas Capital and was previously a director of investment banking and funds management group Grant Samuel.

Malcolm is a former Managing Director of investment banking at County NatWest and its successor organisation Salomon Smith Barney (now Citigroup). He has held various executive roles with Morgan Grenfell (now Deutsche Bank) in Melbourne, Sydney and London.

Malcolm has worked with many high growth companies across various industry sectors and has experience in equity and debt finance, acquisitions and divestments and privatisations. He has led more than 50 initial public offerings and significant secondary offerings for companies, institutions and governments. Mr McComas is a director of Royalco Resources Limited, Australasian Leukaemia and Lymphoma Group, Actinogen Medical Limited, and Chairman of Fitzroy River Corporation Limited.

Malcolm is a member of the Audit Committee and the Remuneration and Nomination Committee.


Gary J Phillips
B Pharm MBA - Chief Executive Officer

Gary joined the Company in 2003 and was appointed Chief Executive Officer and became a member of the Board of Directors in March 2013. He previously held the positions of Commercial Director and Chief Operating Officer. Gary has more than 30 years of operational management experience in the pharmaceutical and healthcare industry in Europe, Asia and Australia.

From 1994 to 1998, he was Chief Executive Officer at Ciba Geigy in Hungary (merged to form Novartis in 1996) where he led the successful launch of a portfolio of new products.  After a period of 3 years as an area manager for Novartis responsible for 9 countries in Asia Pacific in 2001 he joined Novartis Australia as Group Company Head and Chief Executive Officer of its Pharmaceutical Division, successfully launching leading oncology and ophthalmology products. Gary holds a BPharm in Pharmacy with honors from Nottingham University in the UK and an MBA from Henley Management College. Gary is a Graduate Member of the Australian Institute of Company Directors.


William L Delaat
AM BSc - Non-Executive Director

Will has been a member of the Board of Directors since June 2008. He has more than 35 years’ experience in the global pharmaceutical industry, most recently as the Managing Director of the Australian subsidiary of Merck & Co, a position he held from 1997 until his retirement in 2008.

During his career Will has held executive positions in both Europe and Australia for Merck and AstraZeneca. He has a broad depth of experienced in pharmaceutical sales and marketing and has been responsible for numerous international product launches.

Will was Chairman of the pharmaceutical peak body Medicines Australia, and the Pharmaceuticals Industry Council from 2008-2012. He is also the former Chairman of EnGeneIC Ltd, an unlisted Australian biotech company, and a member of other Government appointed Councils and Not-for-Profit Boards. Mr Delaat is a non-executive director of two Sydney based unlisted start-up companies, Well Movement Ltd and Lucky Health Pty Ltd.

Will holds a Bachelor of Science, Physiology & Chemistry, from the University of London.

Will is Chair of the Pharmaxis Audit Committee and a member of the Remuneration and Nomination Committee.


Neil Graham
MBBS, MD, MPH - Non-Executive Director

Neil is an infectious diseases epidemiologist with extensive experience working in biotech and pharmaceutical companies in the development of medicines.

His career has included senior roles overseeing pipeline development and clinical programs at Regeneron (REGN:US), Vertex USA, Trimeris Inc. and Tibotec Pharmaceuticals. 

Neil has considerable depth of scientific expertise in immunology and inflammation and is the author of a number of books and publications including a considerable body of work on respiratory illness.

He was educated at University of Adelaide (MBBS, MD, MPH).  Between 1993 and 1997 he was Associate Professor of Epidemiology at John Hopkins University School of Hygiene and Public Health with research focused on HIV, tuberculosis and hepatitis.


Kathleen M Metters
BS PhD - Non-Executive Director

Dr Kathleen Metters joined the Board of Directors in June 2017 bringing more than 25 years of experience in the discovery and development of novel therapies for treatment of serious diseases. She was formerly the Senior Vice President and Head of Worldwide Basic Research for Merck & Co. with oversight of all the company’s global research projects. In a subsequent role at Merck &Co. She led work on External Discovery and Preclinical Sciences.

Kathleen was President and CEO of biopharmaceutical company Lycera Corp and is currently an independent consultant and senior advisor for Bridge Medicines. Dr Metters is currently a board member of HemoShear Therapeutics, LLC.

Kathleen graduated with a B.S. in biochemistry from the University of Manchester Institute for Science and Technology, and a Ph.D. from Imperial College of Science and Technology in London.

Dr Metters is a member of the Company's Scientific Advisory Board and is chair of the Remuneration and Nomination Committee.


David M McGarvey
BA CAANZ GAICD FGIA - Company Secretary and Chief Financial Officer

David has been Chief Financial Officer and Company Secretary since December 2002. He is a seasoned CFO with thirty years’ experience building and funding Australian based companies from inception to globally successful enterprises.

From 1998 to 2002 David served as Chief Financial Officer of the Filtration and Separations Division of US Filter. From 1985 to 1997 he served as Chief Financial Officer of Memtec Limited. While at Memtec and US Filter, David oversaw the US listing of the company on the Nasdaq Global Market and the New York Stock Exchange and managed numerous international merger and acquisition transactions. From 1975 to 1985, he held various positions at PriceWaterhouseCoopers.

David holds a BA in Accounting from Macquarie University and was admitted to the Chartered Accountants Australia and New Zealand in 1981. David is a Graduate Member of the Australian Institute of Company Directors and a Fellow of Governance Institute of Australia.


Last updated 10th November 2020

Investors, corporate and financial

David McGarvery
Chief Financial Officer & Company Secretary
P | +61 2 9454 7200
E | [email protected] 

Felicity Moffatt
Media Contacts
M| +61 (0) 418 677 701
E | [email protected]  

Gary Phillips
Partner and collaboration contacts
P |  +61 (02) 9454 7200
E |  [email protected]

Clinical trials, product information and medical information
P | Australia Head Office Phone: +61 2 9454 7200
E | [email protected]

Adverse events
E | [email protected]
F | + 61 2 9454 7255

Customer  Information
E | [email protected]

Head Office - Australia
Pharmaxis Ltd
20 Rodborough Road
Frenchs Forest NSW 2086
AUSTRALIA

Mailing Address:
Locked Bag 5015
Frenchs Forest NSW 2086
AUSTRALIA

P | +61 2 9454 7200
F | +61 2 9451 3622
E | [email protected]

Europe

European Mailing Addresses

Pharmaxis Pharmaceutical Limited
25 Moorgate, London, EC2R 6AY, England 

Pharmaxis Europe Limited
c/o Smith and Williamson
Paramount Court, Corrig Road 
Sandyford Business Park, Dublin
Republic of Ireland



Last updated 30th October 2020

Directors

Malcolm McComas – Chairman
Gary Phillips - Chief Executive Officer
Will Delaat – Non Executive Director
Kathleen Metters - Non Executive Director 
Neil Graham - Non Executive Director
David McGarvey - Company Secretary and Chief Financial Officer


Investor relations enquiries

David McGarvey
E | [email protected]

Rudi Michelson (Monsoon Communications)
E | [email protected]


Media enquiries

Felicity Moffatt
E | [email protected]


Partnership and collaboration enquiries

Gary Phillips 
E | [email protected]is.com.au


Registered office

20 Rodborough Road
Frenchs Forest NSW 2086
Australia

Telephone: +61 2 9454 7200
Fax: +61 2 9451 3622
Email: [email protected]
Website: www.pharmaxis.com.au


Securities exchange listings

Pharmaxis shares are listed on the Australian Stock Exchange (Code: PXS)
Pharmaxis American Depositary Receipts are traded on the US over-the-counter market (Code: PXSLY)


Legal advisors

PFM Legal Pty Ltd
Level 7, 257 Clarence Street,
Sydney NSW 2000
Australia


Auditor

PricewaterhouseCoopers
One International Towers Sydney
Watermans Quay
Barangaroo, NSW 2000
Australia


Banks

Westpac Banking Corporation


Share registry

Computershare Investor Services Pty Ltd
Level 3, 60 Carrington Street
Sydney NSW 2000
Australia

Telephone: 1300 855 080 / +61 (03) 9415 4000
Website: http://www.computershare.com.au


Shareholders can access information and services relevant to their holding from the Pharmaxis website under Investors /Shareholder Services


American depositary receipts

BNY Mellon Shareowner Services
P.O. Box 30170
College Station, TX 77842-3170

Telephone: 1-888-BNY-ADRS (1-888-269-2377)
(toll free number for domestic callers)
International: +1 201 680 6825


Last updated 10th November 2020